Rep. Gilbert Ray Cisneros, Jr. Buys Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares

Posted by Stacy Sanders on Apr 10th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN traded down $0.82 during midday trading on Friday, hitting $50.68. 445,338 shares of the stock traded hands, compared to its average volume of 721,118. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The firm has a market capitalization of $2.92 billion, a PE ratio of -74.53, a price-to-earnings-growth ratio of 1.60 and a beta of 0.73. The business’s 50 day moving average price is $51.29 and its two-hundred day moving average price is $49.68.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $53.00, for a total value of $465,711.00. Following the sale, the director directly owned 27,277 shares in the company, valued at approximately $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This trade represents a 3.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 120,881 shares of company stock valued at $6,139,356 in the last quarter. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sit Investment Associates Inc. raised its position in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after acquiring an additional 250 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares in the last quarter. Arizona State Retirement System raised its position in Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after acquiring an additional 277 shares in the last quarter. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares in the last quarter. Finally, Maryland State Retirement & Pension System raised its position in Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock worth $415,000 after acquiring an additional 290 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SUPN shares. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $62.17.

View Our Latest Research Report on Supernus Pharmaceuticals

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.